Target Intelligencev1.0.4

Researchers can query biological databases via PATH 1 to obtain target structure, function, and pathway information (e.g., KEGG, UniProt). This enables rapid validation of a target's relevance to a disease before investing in drug development.

Using PATH 6, analysts can retrieve approved drugs and late-stage pipeline candidates targeting a specific target (e.g., EGFR). This helps identify leading competitors, emerging modalities, and white-space opportunities for portfolio strategy.

PATH 5 enables systematic retrieval of patents covering molecules, medical uses, screening models, and biomarkers related to a target. This supports freedom-to-operate analysis and identifies licensing opportunities or risks.

By searching clinical trials (PATH 4) with drug, indication, and phase filters, teams can assess the competitive landscape of ongoing studies, identify trial endpoints, and inform clinical development plans.

Combining target information (PATH 1) with drug and trial data (PATH 3 & 4) allows identification of alternative indications or complementary drugs already in development, accelerating repurposing strategies.

PatSnap offers tiered API subscription plans for life sciences MCP services, charging based on data volume and tool access. Revenue comes from monthly or annual fees from pharma companies, CROs, and research institutions.

Each MCP tool invocation (search, fetch) can be metered and billed per call. This model suits customers who need sporadic or ad-hoc analyses, paying only for what they use.

Integrate the target intelligence skill as a module within larger R&D platforms (e.g., informatics suites). PatSnap could license the data and skill for a flat annual fee plus a royalty based on platform users.